Capsule Summary Slides

Share

Program Content

Activities

  • KEYLYNK-009
    KEYLYNK-009: Phase II Trial of Maintenance Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy in Untreated Metastatic or Locally Recurrent Inoperable TNBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 07, 2023

  • KEYNOTE-756
    KEYNOTE-756: Phase III Trial of Neoadjuvant Pembrolizumab vs Placebo Plus CT Followed by Adjuvant Pembrolizumab vs Placebo Plus ET in High-Risk, ER+/HER2- EBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 07, 2023

  • ALEXANDRA/Impassion030
    ALEXANDRA/IMpassion030: Phase III Trial of Adjuvant Chemotherapy ± Atezolizumab for Stage II/III Triple-Negative Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 08, 2023

  • CheckMate 7FL Biomarkers
    Phase III CheckMate 7FL: Biomarker Analysis of Addition of Nivolumab vs Placebo to Neoadjuvant CT and Adjuvant ET in High-Risk ER+/HER2- EBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 08, 2023

  • HER2CLIMB-02
    HER2CLIMB-02: Phase III Trial of Trastuzumab Emtansine ± Tucatinib in Previously Treated HER2-Positive MBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 08, 2023

  • NSABPB51/RTOG 1304
    NRG Oncology/NSABP B-51/RTOG 1304: Phase III Trial Evaluating Benefit of Adjuvant Regional Nodal Irradiation in Patients With Early Breast Cancer Converting to Axillary Lymph Node Negativity After Neoadjuvant Chemotherapy
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 08, 2023

  • DEBBRAH – LMC Cohort
    Phase II DEBBRAH: Trastuzumab Deruxtecan in Cohort With HER2+/HER-Low ABC and Leptomeningeal Carcinomatosis
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2023

  • TROPiCS-02 Subgroup Analysis by Age
    TROPiCS-02 Subgroup Analysis by Age: Sacituzumab Govitecan vs Treatment of Physician’s Choice in HR+/HER2- MBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2023

  • NATALEE Adj Ribociclib
    Final iDFS Analysis of NATALEE: Phase III Trial of Adjuvant Ribociclib + Nonsteroidal Aromatase Inhibitor in HR+/HER2- EBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2023

  • Neo N
    BCT1902/IBCSG 61-20 Neo-N: Phase II Trial of Concurrent Nivolumab Plus Neoadjuvant Chemotherapy With and Without Lead-In Nivolumab in Stage I/II TNBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2023

  • monarchE Profiling and ctDNA
    monarchE: Molecular Profiling of Primary Tumor Tissue and ctDNA Detection in Patients With High-Risk, Node-Positive HR+/HER2- EBC Treated With Adjuvant ET ± Abemaciclib
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2023

  • TROPIONBreast01
    TROPION-Breast01: Efficacy and Safety From Phase III Trial of Datopotamab Deruxtecan vs Chemotherapy for Patients With Previously Treated HR+/HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Merck Sharp & Dohme, LLC

Seagen Inc.